Highlights Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Market Closed - Japan Exchange Other stock markets 11:30:00 16/05/2024 am IST			5-day change	1st Jan Change
3,675 ^JPY	-1.47%		-16.72%	-26.44%

10/04	Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy	MT
18/03	Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Final dividend	28/03	FA
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	09/02	MT
Ex-dividend day for interim dividend	28/23/28	FA
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023	10/23/10	CI
Nippon Shinyaku Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	11/23/11	CI
Ex-dividend day for final dividend	30/23/30	FA
Ex-dividend day for interim dividend	29/22/29	FA
Ex-dividend day for final dividend	30/22/30	FA
Capricor Therapeutics, Nippon Shinyaku Enter Marketing Deal for Duchenne Muscular Dystrophy Treatment in US	25/22/25	MT
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of Cap-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S	25/22/25	CI
Clinigen JV To Launch Viltepso Managed Access Program For Duchenne Muscular Dystrophy Patients	29/21/29	MT
Clinigen Group plc Signs Agreement with Nippon Shinyaku	29/21/29	CI
Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku	10/21/10	CI
Ex-dividend day for interim dividend	29/21/29	FA
Zogenix : Secures Orphan Drug Designation for Fintepla in Japan	26/21/26	MT
Nippon Shinyaku Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2021	10/21/10	CI
Nippon Shinyaku Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2021	10/21/10	CI
Nippon Shinyaku Co., Ltd. Announces Dividend for the Year Ended March 31, 2021, Scheduled Start of Payment June 30, 2021; Provides Dividend Guidance for the Second Quarter and Fiscal Year 2022	14/21/14	CI
Ex-dividend day for final dividend	30/21/30	FA
Menarini Group and Nippon Shinyaku Co., Ltd. Enter into an Exclusive License Agreement to Develop and Commercialize Elzonris® (Tagraxofusp) in Japan	29/21/29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Highlights

Filters